JP2005513167A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005513167A5 JP2005513167A5 JP2003557575A JP2003557575A JP2005513167A5 JP 2005513167 A5 JP2005513167 A5 JP 2005513167A5 JP 2003557575 A JP2003557575 A JP 2003557575A JP 2003557575 A JP2003557575 A JP 2003557575A JP 2005513167 A5 JP2005513167 A5 JP 2005513167A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- treatment
- present
- diarrhea
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010028980 Neoplasm Diseases 0.000 description 11
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 206010012735 Diarrhoea Diseases 0.000 description 7
- 230000002062 proliferating effect Effects 0.000 description 5
- 229940125714 antidiarrheal agent Drugs 0.000 description 4
- 239000003793 antidiarrheal agent Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000009097 single-agent therapy Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 2
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 2
- 239000008896 Opium Substances 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 2
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 2
- 235000008191 folinic acid Nutrition 0.000 description 2
- 239000011672 folinic acid Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 229960001691 leucovorin Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229960001027 opium Drugs 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940053867 xeloda Drugs 0.000 description 2
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000002419 Motilin Human genes 0.000 description 1
- 101800002372 Motilin Proteins 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002814 antineoplastic antimetabolite Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- ZREIPSZUJIFJNP-UHFFFAOYSA-K bismuth subsalicylate Chemical compound C1=CC=C2O[Bi](O)OC(=O)C2=C1 ZREIPSZUJIFJNP-UHFFFAOYSA-K 0.000 description 1
- 229960000782 bismuth subsalicylate Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960005493 difenoxin Drugs 0.000 description 1
- UFIVBRCCIRTJTN-UHFFFAOYSA-N difenoxin Chemical compound C1CC(C(=O)O)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 UFIVBRCCIRTJTN-UHFFFAOYSA-N 0.000 description 1
- 229960004192 diphenoxylate Drugs 0.000 description 1
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- 150000003883 epothilone derivatives Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 229940050957 opium tincture Drugs 0.000 description 1
- -1 opium tincture Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34862202P | 2002-01-14 | 2002-01-14 | |
| US41617302P | 2002-10-04 | 2002-10-04 | |
| PCT/EP2003/000232 WO2003057217A1 (en) | 2002-01-14 | 2003-01-13 | Combinations comprising epothilones and anti-metabolites |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005513167A JP2005513167A (ja) | 2005-05-12 |
| JP2005513167A5 true JP2005513167A5 (enExample) | 2006-03-02 |
Family
ID=26995808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003557575A Ceased JP2005513167A (ja) | 2002-01-14 | 2003-01-13 | エポシロン誘導体と代謝拮抗剤からなる組合せ |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20060089327A1 (enExample) |
| EP (2) | EP1469847A1 (enExample) |
| JP (1) | JP2005513167A (enExample) |
| KR (1) | KR20040078123A (enExample) |
| CN (1) | CN1615136A (enExample) |
| AU (1) | AU2003235761A1 (enExample) |
| BR (1) | BR0306861A (enExample) |
| CA (1) | CA2471509A1 (enExample) |
| IL (1) | IL162595A0 (enExample) |
| MX (1) | MXPA04006822A (enExample) |
| NO (1) | NO20043279L (enExample) |
| NZ (1) | NZ533940A (enExample) |
| PL (1) | PL369670A1 (enExample) |
| RU (1) | RU2346686C2 (enExample) |
| TW (1) | TWI341728B (enExample) |
| WO (1) | WO2003057217A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6242469B1 (en) | 1996-12-03 | 2001-06-05 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| CA2440555A1 (en) | 2001-03-14 | 2002-09-19 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| WO2002074042A2 (en) * | 2001-03-19 | 2002-09-26 | Novartis Ag | Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative |
| BR0315169A (pt) * | 2002-10-09 | 2005-08-23 | Kosan Biosciences Inc | Referência cruzada a pedidos de patente relacionados |
| BRPI0414043A (pt) * | 2003-09-02 | 2006-10-24 | Novartis Ag | tratamento de cáncer com epotilonas |
| US20050171167A1 (en) | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
| US20060121511A1 (en) | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
| US20090099103A1 (en) * | 2006-04-05 | 2009-04-16 | Novartis Ag. | Combinations of therapeutic agents for treating cancer |
| CN101415409B (zh) * | 2006-04-05 | 2012-12-05 | 诺瓦提斯公司 | 用于治疗癌症的治疗剂的组合 |
| WO2011146638A1 (en) | 2010-05-18 | 2011-11-24 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2802005A (en) | 1957-08-06 | S-eluorourace | ||
| US2705727A (en) | 1952-07-10 | 1955-04-05 | Du Pont | Synthesis of ureas |
| US2933498A (en) | 1954-12-28 | 1960-04-19 | Burroughs Wellcome Co | 7-aminothiazolo-(5,4-d) pyrimidine |
| US3116282A (en) | 1960-04-27 | 1963-12-31 | Upjohn Co | Pyrimidine nucleosides and process |
| US4393064A (en) | 1976-03-05 | 1983-07-12 | Sri International | Process and composition for treatment of leukemia and process for preparing the same |
| US4357324A (en) | 1981-02-24 | 1982-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine |
| US4760135A (en) | 1984-09-06 | 1988-07-26 | University Of Kentucky Research Foundation | Phloretin and phlorizin derivative containing compounds |
| DE3587500T2 (de) | 1984-12-04 | 1993-12-16 | Lilly Co Eli | Tumorbehandlung bei Säugetieren. |
| DE3773716D1 (de) | 1986-03-24 | 1991-11-21 | Nippon Kayaku Kk | Verfahren zur herstellung von monosodiumsalz und dessen monohydrat von 1-beta-d-arabinofuranosylcytosin-5'stearylphosphat und diese enthaltende pharmazeutische zusammensetzung. |
| EP0443028B1 (en) * | 1989-01-05 | 1993-09-29 | Otsuka Pharmaceutical Co., Ltd. | Non-injection carcinostatic agent for suppressing occurrence of inflammation due to 5-fluorouracil and method for curing cancer |
| KR0148589B1 (ko) | 1991-05-27 | 1998-11-02 | 고바야시 유끼오 | 항종양 효과의 상승 및 종양의 치료를 위한 조성물 및 키트 |
| DE4138042C2 (de) | 1991-11-19 | 1993-10-14 | Biotechnolog Forschung Gmbh | Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel |
| AU671491B2 (en) | 1992-12-18 | 1996-08-29 | F. Hoffmann-La Roche Ag | N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines |
| NZ334821A (en) | 1996-08-30 | 2000-12-22 | Novartis Ag | Method for producing epothilones |
| CN100344627C (zh) | 1996-11-18 | 2007-10-24 | 生物技术研究有限公司(Gbf) | 埃坡霉素c、其制备方法以及作为细胞抑制剂和植物保护剂的应用 |
| US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| US6380394B1 (en) * | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
| US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
| EP1052974B1 (en) | 1998-02-05 | 2009-05-20 | Novartis AG | Pharmaceutical formulation containing epothilone |
| US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| US6302838B1 (en) * | 1998-02-25 | 2001-10-16 | Novartis Ag | Cancer treatment with epothilones |
| ATE307123T1 (de) | 1998-02-25 | 2005-11-15 | Sloan Kettering Inst Cancer | Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen |
| FR2775187B1 (fr) * | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
| EP1135470A2 (en) | 1998-11-20 | 2001-09-26 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
| EP1140944B1 (en) * | 1998-12-22 | 2003-08-27 | Novartis AG | Epothilone derivatives and their use as antitumor agents |
| ATE254615T1 (de) * | 1999-02-22 | 2003-12-15 | Biotechnolog Forschung Gmbh | C-21 modifizierte epothilone |
| JP2002541200A (ja) * | 1999-04-14 | 2002-12-03 | デイナ−ファーバー キャンサー インスティチュート，インコーポレイテッド | 癌の処置のための方法および組成物 |
| GB9918429D0 (en) * | 1999-08-04 | 1999-10-06 | Novartis Ag | Organic compounds |
| AU2001266583A1 (en) * | 2000-05-26 | 2001-12-11 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
| CA2440555A1 (en) * | 2001-03-14 | 2002-09-19 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| TWI287986B (en) * | 2001-12-13 | 2007-10-11 | Novartis Ag | Use of Epothilones for the treatment of the carcinoid syndrome |
-
2003
- 2003-01-13 MX MXPA04006822A patent/MXPA04006822A/es active IP Right Grant
- 2003-01-13 KR KR10-2004-7010853A patent/KR20040078123A/ko not_active Ceased
- 2003-01-13 WO PCT/EP2003/000232 patent/WO2003057217A1/en not_active Ceased
- 2003-01-13 EP EP20030729249 patent/EP1469847A1/en not_active Ceased
- 2003-01-13 CN CNA03802215XA patent/CN1615136A/zh active Pending
- 2003-01-13 PL PL03369670A patent/PL369670A1/xx unknown
- 2003-01-13 JP JP2003557575A patent/JP2005513167A/ja not_active Ceased
- 2003-01-13 RU RU2004124943/15A patent/RU2346686C2/ru not_active IP Right Cessation
- 2003-01-13 IL IL16259503A patent/IL162595A0/xx unknown
- 2003-01-13 NZ NZ533940A patent/NZ533940A/en not_active IP Right Cessation
- 2003-01-13 AU AU2003235761A patent/AU2003235761A1/en not_active Abandoned
- 2003-01-13 CA CA002471509A patent/CA2471509A1/en not_active Abandoned
- 2003-01-13 BR BR0306861-7A patent/BR0306861A/pt not_active Application Discontinuation
- 2003-01-13 US US10/501,207 patent/US20060089327A1/en not_active Abandoned
- 2003-01-13 EP EP08169239A patent/EP2030618A3/en not_active Withdrawn
- 2003-01-13 TW TW092100606A patent/TWI341728B/zh not_active IP Right Cessation
-
2004
- 2004-08-05 NO NO20043279A patent/NO20043279L/no not_active Application Discontinuation
-
2009
- 2009-08-12 US US12/539,891 patent/US20090298791A1/en not_active Abandoned
-
2010
- 2010-12-13 US US12/966,575 patent/US20110082101A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2785349B2 (en) | Combination treatment of cancer | |
| JP2024133475A5 (enExample) | ||
| JP2024133474A5 (enExample) | ||
| IL311471A (en) | Combination therapy | |
| JP2012500180A5 (enExample) | ||
| HUE029677T2 (hu) | Készítmények centrálisan mediált émelygés és hányás kezelésére | |
| JP2005513167A5 (enExample) | ||
| MX2013013014A (es) | Metodo para el tratamiento de tumores solidos avanzados. | |
| JP2020502261A5 (enExample) | ||
| JP2020500864A5 (enExample) | ||
| US11083722B2 (en) | Combination therapies for the treatment of breast cancer | |
| KR20240112931A (ko) | 암 치료를 위한 cdk4 억제제 | |
| CN102438608A (zh) | 包含ave8062和索拉非尼的抗肿瘤组合 | |
| JP2005535608A5 (enExample) | ||
| TWI341728B (en) | Combinations comprising epothilones and anti-metabolites | |
| JP6370801B2 (ja) | 肝疾患または肝障害の治療のための使用および方法 | |
| JP2020517739A (ja) | リンパ節陽性の初期ホルモン受容体陽性かつヒト上皮成長因子受容体２陰性乳癌の補助治療のための内分泌療法とアベマシクリブとの組み合わせ | |
| JP2006508118A5 (enExample) | ||
| WO2023281413A1 (en) | Methods and dosing regimens comprising pf-06873600 for the treatment of cancer | |
| CN118338901A (zh) | 用于治疗癌症的cdk4抑制剂 | |
| JP2019011320A (ja) | ペマフィブラートを含有する医薬 | |
| AU2020346384A1 (en) | Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma | |
| US20030139430A1 (en) | Use of organic compounds | |
| CN120302974A (zh) | 喹诺林化合物治疗甲状腺癌的用途 | |
| TW202416992A (zh) | 雌激素受體降解劑之給藥方案 |